Adequate levels of vitamin D reduces complications, death among COVID-19 patients

Hospitalized COVID-19 patients who were vitamin D sufficient, with a blood level of 25-hydroxyvitamin D of at least 30 ng/mL (a measure of vitamin D status), had a significant decreased risk for adverse clinical outcomes including becoming unconscious, hypoxia (body starved for oxygen) and death. In addition, they had lower blood levels of an inflammatory marker (C-reactive protein) and higher blood levels of lymphocytes (a type of immune cell to help fight infection).

"This study provides direct evidence that vitamin D sufficiency can reduce the complications, including the cytokine storm (release of too many proteins into the blood too quickly) and ultimately death from COVID-19," explained corresponding author Michael F. Holick, PhD, MD, professor of medicine, physiology and biophysics and molecular medicine at Boston University School of Medicine.

A blood sample to measure vitamin D status (measured serum level of 25-hydroxyvitamin D) was taken from 235 patients were admitted to the hospital with COVID-19. These patients were followed for clinical outcomes including clinical severity of the infection, becoming unconscious, having difficulty in breathing resulting in hypoxia and death. The blood was also analyze for an inflammatory marker (C-reactive protein) and for numbers of lymphocytes. The researchers then compared all of these parameters in patients who were vitamin D deficient to those who were vitamin D sufficient.

In patients older than 40 years they observed that those patients who were vitamin D sufficient were 51.5 percent less likely to die from the infection compared to patients who were vitamin D deficient or insufficient with a blood level of 25-hydroxyvitamin D less than 30 ng/mL.

Holick, who most recently published a study which found that a sufficient amount of vitamin D can reduce the risk of catching coronavirus by 54 percent, believes that being vitamin D sufficient helps to fight consequences from being infected not only with the corona virus but also other viruses causing upper respiratory tract illnesses including influenza. "There is great concern that the combination of an influenza infection and a coronal viral infection could substantially increase hospitalizations and death due to complications from these viral infections."

According to Holick this study provides a simple and cost-effective strategy to improve one's ability to fight the corona virus and reduce COVID-19's adverse clinical outcomes, including requiring ventilator support, overactive immune response leading to cytokine storm and death. "Because vitamin D deficiency and insufficiency is so widespread in children and adults in the United States and worldwide, especially in the winter months, it is prudent for everyone to take a vitamin D supplement to reduce risk of being infected and having complications from COVID-19."

Zhila Maghbooli, Mohammad Ali Sahraian, Mehdi Ebrahimi, Marzieh Pazoki, Samira Kafan, Hedieh Moradi Tabriz, Azar Hadadi, Mahnaz Montazeri, Mehrad Nasiri, Arash Shirvani, Michael F Holick.
Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection.
PLOS ONE, 2020. doi: 10.1371/journal.pone.0239799

Most Popular Now

Sinovac reports preliminary Phase I/II results of …

Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced that the inactivated COVID-19 vaccin...

CureVac expected to receive up to 252 million euro…

CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) in clinical trials...

Pfizer and BioNTech announce data from preclinical…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary preclinical data in mouse and non-human primate models from their BNT162b2 mRNA-based v...

COVID-19 vaccine AZD1222 clinical trials resumed i…

Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA)...

Antiviral used to treat cat coronavirus also works…

Researchers at the University of Alberta are preparing to launch clinical trials of a drug used to cure a deadly disease caused by a coronavirus in cats that they expect ...

Search for COVID-19 drugs boosted by SARS discover…

An extensive search and testing of current drugs and drug-like compounds has revealed compounds previously developed to fight SARS might also work against COVID-19. Us...

COVID-19 study links strict social distancing to m…

Using public transportation, visiting a place of worship, or otherwise traveling from the home is associated with a significantly higher likelihood of testing positive wi...

Pfizer and BioNTech propose expansion of pivotal C…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced that they have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrol...

Vitamin D deficiency may raise risk of getting COV…

In a retrospective study of patients tested for COVID-19, researchers at the University of Chicago Medicine found an association between vitamin D deficiency and the like...

Improving FDA's COVID-19 vaccine authorization and…

On March 28, the Food and Drug Administration (FDA) exercised its Emergency Use Authorization (EUA) authority to allow the use of hydroxychloroquine for the treatment of ...

Steroid found to improve survival of critically il…

A new international study published today has shown that treating critically ill patients with COVID-19 with the steroid hydrocortisone improves their chances of recovery...

Abbott's fast, $5, 15-minute, easy-to-use COVID-19…

Abbott (NYSE: ABT) announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its BinaxNOWâ„¢ COVID-19 Ag Card rapid test f...